

**REMARKS**

Applicants filed by facsimile the Supplemental Amendment (March 1, 2002) on March 1, 2002. To simplify the number of papers, applicants request that the Examiner not enter that Supplemental Amendment and to enter the following amendments prior to action by the Examiner.

Applicants have amended claim 41. The attached Appendix shows the added language to claim 41 by underlining. The amendment makes certain language in claim 41 more consistent with language in pending claim 23. The amendment is not made for patentability purposes and does not narrow the scope of the claim. The amendment to claim 41 in this paper is slightly different than the amendment in the Supplemental Amendment (March 1, 2002). The language in the current amendment is closer to the language of claim 23 than the language in the Supplemental Amendment (March 1, 2002).

Applicants have also added claims 42 through 138. Claim 42 in this amendment is slightly different than claim 42 in the Supplemental Amendment (March 1, 2002). The difference in the language is not made for purposes of patentability and does not narrow the scope of claim 42. New claims 42 through 138 are supported by disclosure throughout the specification.

Claims 22 to 25 and 37 to 138 are presently pending and under consideration.

LAW OFFICES  
NNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, D.C. 20004  
202-408-4000

Please grant any extensions of time required to enter this paper and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:



M. Paul Barker  
Reg. No. 32,013

Dated: March 5, 2002

LAW OFFICES  
FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 T STREET, N.W.  
WASHINGTON, DC 20004  
202-408-4000

Appendix to Amendment (March 5, 2002)IN THE CLAIMS:

Please amend the claims to read as follows:

41. (Amended) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding an interleukin-1 inhibitor (IL-1i) polypeptide, having interleukin-1 (IL-1) inhibitory activity, wherein said polypeptide is selected from the group consisting of:

A) a polypeptide comprising all or an IL-1 inhibitory fragment of the amino acid sequence:

(U) (X) P S G R K S S K M Q A F R I W D V N Q K T F Y L R N  
N Q L V A G Y L Q G P N V N L E E K I D V V P I E P H A  
L F L G I H G G K M C L S C V K S G D E T R L Q L E A V  
N I T D L S E N R K Q D K R F A F I R S D S G P T T S F  
E S A A C P G W F L C T A M E A D Q P V S L T N M P D E  
G V M V T K F Y F Q E D E

wherein (U) is M or nothing and (X) is R or P; and

B) a polypeptide that is at least about 90% homologous to the amino acid sequence set forth in A).

LAW OFFICES  
INNFCAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000